House, Senate Differ In Treating FDA China Syndrome
This article was originally published in The Tan Sheet
Appropriators in the House and Senate endorse FDA’s plan to spend $10 million more on inspections in China in 2013, but only the Senate approves increasing the agency’s budget to cover the costs. FDA’s request for China inspections includes $5.6 million for inspections at drug facilities.
You may also be interested in...
Sen. Hatch on path to re-election; Senate passes FDA Safety and Innovation Act; DSM petitions FDA for folic acid fortification of masa flour; Nutrition 21 returns under new management; ZO Skin Health defends trademarks; more news In Brief.
A Senate FDA appropriation report says the guidance would enhance the agency’s ability to inspect and assess industry practices for manufacturing botanical dietary supplements. A National Center for Natural Products Research official says most botanical ingredients lack standard identity tests.
Sanofi-Synthelabo extends its offer for Aventis U.S. shareholders to exchange their shares for Sanofi stock until June 30, Sanofi announces. The original deadline of May 28 was extended pending a decision by the French stock market regulator Autrite des Marches Financiers to set an expiration date. Sanofi has articulated a desire to close the $65 bil. merger in the second quarter. The firm also is awaiting final clearance from the Federal Trade Commission. Aventis accepted Sanofi's offer April 25 (1"The Tan Sheet" May 3, 2004, p. 8)...